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Regulator of G protein signaling 2 (RGS2) controls signaling
by receptors coupled to the Gq/11 class heterotrimeric G pro-
teins. RGS2 deficiency causes several phenotypes in mice and
occurs in several diseases, including hypertension in which a
proteolytically unstable RGS2 mutant has been reported. How-
ever, themechanisms and functions of RGS2 proteolysis remain
poorly understood. Here we addressed these questions by iden-
tifying degradation signals in RGS2, and studying dynamic reg-
ulation of Gq/11-evoked Ca2 signaling and vascular contrac-
tion. We identified a novel bipartite degradation signal in the
N-terminal domain of RGS2. Mutations disrupting this signal
blunted proteolytic degradation downstream of E3 ubiquitin
ligase binding to RGS2. Analysis of RGS2 mutants proteolyzed
at various rates and the effects of proteasome inhibition indi-
cated that proteolytic degradation controls agonist efficacy by
setting RGS2 protein expression levels, and affecting the rate at
which cells regain agonist responsiveness as synthesis of RGS2
stops. Analyzing contraction of mesenteric resistance arteries
supported the biological relevance of this mechanism. Because
RGS2 mRNA expression often is strikingly and transiently up-
regulated and then down-regulated upon cell stimulation, our
findings indicate that proteolytic degradation tightly couples
RGS2 transcription, protein levels, and function.Together these
mechanisms provide tight temporal control of Gq/11-coupled
receptor signaling in the cardiovascular, immune, and nervous
systems.
Signal transduction by G protein–coupled receptors
(GPCRs)2 in mammalian cells is regulated by diverse mecha-
nisms that determine agonist response amplitude (efficacy),
kinetics, desensitization, and resensitization, thereby providing
novel drug targets to modulate GPCR signaling in many dis-
eases (1). Among these regulatorymechanisms, thosemediated
by the regulator of G protein signaling (RGS) family of proteins
are crucial as indicated by diverse phenotypes ofmice lacking cer-
tain RGS proteins or expressing RGS-insensitive G protein
mutants (2, 3) and humans bearing mutations in RGS-encoding
genes (4–6). These phenotypes are thought to occur because
many RGS proteins regulate the amplitude and kinetics of GPCR
signaling by functioning asGTPase-activatingproteins (GAPs) for
G protein -subunits (7), and because certain RGS proteins also
affect cell signaling by GAP-independent mechanisms (8).
Among 30 RGS proteins encoded by the human genome,
RGS2 is of particular interest. RGS2 is a GAP that acts prefer-
entially toward Gq/11 class -subunits relative to Gi/o -sub-
units (9–12), and has several GAP-independent functions (8, 13,
14). RGS2 is expressed in many organs, tissues, and cell types
where it participates indiverse physiological anddisease processes
includingTcell activation (15), bloodpressure regulation (16–20),
cardiac hypertrophy andheart failure (21–23), renal hemodynam-
ics (20), anxiety (15, 24), and certain cancers (25).
A key emerging concept is that physiological and disease pro-
cesses are strikingly sensitive even to modest changes in RGS2
function or expression level. For example, loss of just one RGS2
allele is sufficient to elevate blood pressure in mice (16), rare
missense mutations that reduce RGS2 protein expression are
associated with hypertension in humans (5, 6), and RGS2
down-regulation occurs in human hypertension (26). Further-
more, in several tissues and cell systems RGS2 mRNA expres-
sion is strikingly and transiently up- and then down-regulated
in response to cell stimulation (11, 27–34), potentially serving
as an inducible feedback loop that attenuates or desensitizes
GPCR signaling.
Such evidence has motivated efforts to identify mechanisms
that regulate RGS2 expression or function, which could provide
new insight into disease pathogenesis or novel targets for ther-
apeutic development. Among such mechanisms, proteolytic
degradation of RGS2may be particularly important. RGS2 pro-
tein half-life is short (30 min) because of ubiquitin- and pro-
teasome-mediated proteolysis (35–37). Targeting this process
has therapeutic potential because cardiotonic steroids such as
digoxin inhibit RGS2 degradation and protect inmousemodels
against cardiac injury in an RGS2-dependent manner (38).
Mechanisms that mediate proteolytic degradation of RGS2
are complex. One mechanism is the acetylated N-end (Ac/N)
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rule pathway involving the identity of the amino acid at position
2 in RGS2, the N-recognin TEB4 (MARCH6), and theN-termi-
nal acetylase Naa60 (37). However, other mechanisms have
been implicated because RGS2 degradation also requires a
ubiquitin E3 ligase complex (CUL4B/DDB1/FBXO44) un-
linked to the N-end rule pathway (36). RGS2 degradation is a
regulated process, as indicated by the inhibitory effects of car-
diotonic steroids (38, 39), protein kinase C (PKC) activators
(40), or a cGMP-dependent protein kinase (cGK) inhibitor (41).
Whether such effects occur by targeting recognition of RGS2by
the Ac/N-end rule and/or CUL4B/DDB1/FBXO44 pathways is
unknown.
Less well-understood is how proteolytic degradation of
RGS2 affects GPCR signaling. A rapidly proteolyzed hyperten-
sion-associated RGS2 mutant (Q2L) exhibits reduced function
(35), but whether this effect occurs by proteolytic degradation
or other mechanisms has not been established. Similarly,
although knock down of Ac/N-end rule components blunts
RGS2 proteolysis and enhances inhibition of Gq-mediated ERK
activation (37), whether this effect on cell signaling occurs spe-
cifically by inhibiting proteolytic degradation of RGS2 as
opposed to other molecules is unclear. Moreover, whereas
knockdown of the CUL4B/DBB1/FBXO44 complex inhibits
RGS2degradation (36), its effectonGPCRsignalingwasnot inves-
tigated. Lastly, whether RGS2 proteolysis regulates GPCR signal-
ing amplitude, kinetics, desensitization, or resensitization has not
been studied.
Here our goals were to determine how RGS2 is targeted for
ubiquitin- and proteasome-mediated degradation and to estab-
lish how Gq/11-mediated GPCR signaling is regulated by RGS2
proteolysis. Rather than knocking down components of the
N-end rule or other pathways, which could have pleiotropic
effects on cell signaling, we have used a structure-function
approach to identify and characterize degradation signals in
RGS2. By analyzing RGS2 mutants that degrade faster or more
slowly than the wild-type protein and assessing the impact of
proteasome inhibition, we have identified novel degradation
signals and provided direct evidence indicating that proteolytic
degradation of RGS2 regulates the amplitude and dynamics of
Gq/11-mediated GPCR signaling.
Results
RGS2 degradation requires a novel N-terminal bipartitemotif
BecauseN-terminal acetylation and the identity of the amino
acid at position 2 in RGS2 are the only features of this protein
shown thus far to affect proteolytic degradation, our first goal
was to conduct a more comprehensive identification of motifs
or domains that are necessary and sufficient for RGS2 proteol-
ysis. Our approach was guided by the domain structure of
RGS2, a 211-residue protein containing an80-residue N-ter-
minal region, followed by the RGS domain that is necessary and
sufficient for GAP activity, and a short C-terminal tail (Fig. 1A).
We began by studying the degradation rates of RGS2 translated
from four previously identified alternative in-frame initiation
sites at methionine 1, 5, 16, and 33 (Met-1, Met-5, Met-16,
Met-33) (Fig. 1, A and B) (31, 42–44) and to explore the role of
the N-terminal region. Which of these alternative translation
products are expressed endogenously in cells or tissues remains
unclear because of low expression, rapid degradation, or limi-
tations of antibodies used for detection. Regardless, the N-end
rule machinery is predicted to recognize each of these alterna-
tive translation products based on the identity of the amino acid
residue immediately following the initiating methionine (i.e.
Gln-2, Phe-6,Asp-17, Lys-34) (45). To studyRGS2degradation,
we tagged the protein at its C terminus with three copies of the
FLAG epitope (RGS2(3xFLAG)), which preserves function (see
below). To simplify analysis, single translation products initi-
ated only at methionine 1, 5, 16, or 33 were produced by chang-
ing other alternative in-frame start sites to leucine codons.Deg-
radation rates of RGS2(3xFLAG) initiated at single translation
start sites were determined by quantitative immunoblotting
of transfected HEK 293 cell lysates harvested over time after
inhibiting new protein synthesis with cycloheximide (CHX)
(Fig. 1C), and by pulse-chase labeling experiments.3 Results
indicated that RGS2 initiated atmethionine 1 or 5was degraded
more rapidly than RGS2 initiated atmethionine 16 or 33 (Fig. 1,
C andD), suggesting that a motif between methionine 5 and 16
promotes RGS2 degradation.
To test this hypothesis, we generated small internal dele-
tions in RGS2(3xFLAG) initiated at methionine 1 (Met-1–
RGS2(3xFLAG)) (Fig. 2A) and analyzed their effects on degra-
dation rates followingCHX treatment. Deletion of residues 5–9
impaired RGS2 degradation whereas removing residues 8–12
3 S. M. Kanai and K. J. Blumer, unpublished data.
Figure1. RGS2 synthesized fromalternative translation initiation sites is
degradedat different rates.A,domain structure of RGS2producedby alter-
native translation initiation. The RGS domain is flanked by an N-terminal
region that contains multiple translation start codons numbered by their
position in the longest open reading frame, as indicated by solid vertical bars
and arrows. Single translation products initiated from a given methionine
residue were produced by changing all other alternative methionine codons
to leucine codons, and tagging them at their C terminus with the 3xFLAG
epitope. B, RGS2(3xFLAG) produced in HEK 293 cells by translation initiated
from single alternative methionine codons. C, proteolytic degradation of
RGS2(3xFLAG) initiated at single alternative translation start sites. Trans-
fected HEK 293 cells expressing RGS2(3xFLAG) initiated at the indicated
methionine codons were treated with cycloheximide (CHX) and analyzed at
the indicated time points by immunoblotting to detect RGS2(3xFLAG)
remaining. D, quantification of RGS2(3xFLAG) protein levels detected by
immunoblotting following addition of CHX. Error bars denote S.E. *, p 0.05;
**, p  0.01 versus Met-1–RGS2(3xFLAG). Data shown are representative of
three or more independent experiments.
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or 10–15 had insignificant effect (Fig. 2, B and C), suggesting
that the former deletion disrupted an internal degradation-pro-
moting motif. This result also suggested that the N-terminal
residue of RGS2 is not the sole determinant of proteolysis
because the 5–9 mutant still contains a glutamine residue at
position 2, which is hypothesized to promote degradation by
the Ac/N-end rule.
Features of the degradation-promoting motif in residues
5–9 were identified by point mutagenesis of Met-1–RGS2
(3xFLAG). Because this region lacks charged or polar residues,
its hydrophobic character may be functionally important.
Indeed, substituting residues 6 or 7 with aspartic acid (Fig. 2D)
markedly impaired degradation ofMet-1–RGS2(3xFLAG) (Fig.
2, E and F), whereas an aspartic acid substitution at position 9
had insignificant effect (Fig. 2, E and F). In contrast, the specific
amino acid sequence of this hydrophobic regionwas unimport-
ant because scrambling its sequence (Fig. 2G) did not affect
degradation kinetics (Fig. 2,H and I). Therefore, degradation of
RGS2 requires a motif composed of hydrophobic residues near
the N terminus.
Whereas the preceding results indicated that proteolytic
degradation of wild-type RGS2 is not determined solely by the
amino acid at position 2 according to the Ac/N-end rule, deg-
radation of the hypertension-associated missense mutant
(RGS2-Q2L) (5, 6, 46) nevertheless may be determined mainly
by this mechanism because of the presence of a destabilizing
leucine residue at position 2. We tested this hypothesis by
determining the rate that Met-1–RGS2–Q2L(3xFLAG) is
degraded in HEK 293 cells when residues 5–9 were deleted or
the hydrophobic character of this region was disrupted by an
F6D substitution (Fig. 3A). Results showed that the degradation
ofMet-1–RGS2–Q2L(3xFLAG) is strikingly impaired by either
the 5–9 or F6Dmutation (Fig. 3, B and C), indicating that the
proteolytic degradation of this hypertension-associated formof
RGS2 also requires this internal hydrophobic motif.
To determine whether this hydrophobic motif promotes
degradation in vascular smooth muscle cells, in which RGS2
regulates vascular reactivity to control blood pressure (18, 41,
47), we analyzed expression of RGS2 as an indicator of protein
stability in transfected A7r5 vascular smooth muscle cells (Fig.
3D). Consistent with prior studies of the hypertension-associ-
Figure 2. A novel hydrophobic degradation signal is located near the N
terminus of RGS2. A, schematic of internal deletion mutants of Met-1–
RGS2(3xFLAG). Mutants are designated by which residues were deleted as
indicated by dotted lines. B, proteolytic degradation of deletion mutants fol-
lowing addition of CHX. C, quantification of degradation rates. Error bars
denote S.E. *, p 0.05 versusMet-1–RGS2(3xFLAG).D, N-terminal amino acid
sequences of wild-type Met-1–RGS2(3xFLAG) and point mutant forms indi-
cated by residues highlighted. E, proteolytic degradation of Met-1–
RGS2(3xFLAG) and the indicatedmutants following addition of CHX. F, quan-
tification of RGS2(3xFLAG) protein levels detected by immunoblotting
following addition of CHX. Error bars denote S.E. *, p  0.05; **, p  0.01
versus Met-1–RGS2(3xFLAG). G, N-terminal amino acid sequences of wild-
type Met-1–RGS2(3xFLAG) and mutants (denoted SCR1 and SCR2) in
which residues at positions 5–9 were scrambled as indicated by highlight-
ing. H, proteolytic degradation of Met-1–RGS2(3xFLAG) and the indicated
mutants following addition of CHX. I, quantification of RGS2(3xFLAG) pro-
tein levels detected by immunoblotting following addition of CHX. Error
bars denote S.E. Data shown are representative of three or more indepen-
dent experiments.
Figure 3. Proteolytic degradation of a hypertension-associated RGS2
missensemutant requires the N-terminal hydrophobic degradation sig-
nal. A, N-terminal amino acid sequences of wild-type Met-1–RGS2(3xFLAG),
the hypertension-associated Q2L variant, and the Q2L variant bearing the
indicated deletion and point mutations that inactivate the N-terminal
hydrophobic degradation motif. B, proteolytic degradation of the indi-
cated RGS2(3xFLAG) mutants following addition of CHX. Error bars denote
S.E. C, quantification of degradation rates of the indicated RGS2(3xFLAG)
mutants. D, relative expression levels of Met-1–RGS2(3xFLAG) and its indi-
cated variants in A7r5 vascular smooth muscle cells. GFP and actin pro-
vided transfection and loading controls, respectively. E, proteasome-
dependent expression of Met-1–RGS2(3xFLAG) and Met-1–RGS2-Q2L
(3xFLAG) in A7r5 cells. Data shown are representative of three or more
independent experiments.
RGS2 proteolysis dynamically regulates Gq/11 signaling
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ated RGS2(Q2L) mutant, the Q2L mutant form of Met-1–
RGS2(3xFLAG) was poorly expressed in A7r5 cells (Fig. 3D)
because of proteasome-mediated degradation (Fig. 3E).
However, introducing the F6D substitution intoMet-1–RGS2–
Q2L(3xFLAG) dramatically increased expression in the ab-
sence of the proteasome inhibitor MG-132 (Fig. 3D). Similarly,
controls showed that Met-1–RGS2–F6D(3xFLAG) was ex-
pressed more highly than wild-type Met-1–RGS2(3xFLAG).
Thus, the hydrophobic motif proximal to the N terminus func-
tions in a non-cell type–specific manner to determine the
expression level of wild-type and a hypertension-associated
mutant form of RGS2.
Although the preceding results indicated that a hydrophobic
motif near the N terminus is required for RGS2 degradation,
the results of further experiments indicated that this motif is
insufficient to promote proteolysis and instead cooperates with
a second internal signal composed of an amphipathic -helix.
This hypothesis was suggested initially by analyzing degrada-
tion of GFP fusion proteins bearing various regions of the RGS2
N-terminal domain (Fig. 4A). Fusing the entire N-terminal
Figure 4. Proteolytic degradation of RGS2 requires an amphipathic -helix. A, Met-1–RGS2-GFP fusion proteins. Met-1–GFP consists of full-length Met-
1–RGS2 fused at its C terminus to GFP. The previously described amphipathic -helix is indicated (shaded). Other fusion proteins are designated according to
which portion of the RGS2N-terminal domainwas fused toGFP, orwhich portionwithin this domainwas deleted, as indicated by residueswithin parentheses.
B, expression of the indicated RGS2-GFP variants in transfected HEK 293 cells detected by immunoblotting. Proteolytically stable degradation products are
indicated with *. C, proteolytic degradation of the indicated fusion proteins following addition of CHX. D, quantification of proteolytic degradation of the
indicated fusion proteins. Error bars denote S.E. *, p  0.05 versus (1–80)-GFP. E, helical wheel representation of the amphipathic -helix, indicating the
hydrophobic residues (gray) and mutated residues (dashed circles). F, amino acid sequence within the amphipathic -helix and substitutions affecting its
hydrophobic face (highlighted residues). G, proteolytic degradation of Met-1–RGS2(3xFLAG) and the indicated mutants following addition of CHX. H, quanti-
fication of RGS2(3xFLAG) protein levels detected by immunoblotting following addition of CHX. Error bars denote S.E. *, p  0.01; **, p  0.001 versus
Met-1–RGS2(3xFLAG). Data shown are representative of three or more independent experiments.
RGS2 proteolysis dynamically regulates Gq/11 signaling
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domain of RGS2 (residues 1–80) to GFP was sufficient to pro-
mote degradation relative to untagged GFP (Fig. 4, B–D). In
contrast, deleting residues 30–50 of this RGS2-GFP fusion pro-
tein, which removes a previously described amphipathic -
helical region but preserves the N-terminal hydrophobic motif,
strikingly impaired proteolytic degradation (Fig. 4, B–D), indi-
cating that the hydrophobic N-terminal motif is insufficient.
These results were extended by analyzing point mutations
affecting the hydrophobic face of the amphipathic -helical
region of Met-1–RGS2(3xFLAG) (Fig. 4, E–H). Results showed
that degradation of the L45D or L45D,L49D mutant forms of
Met-1–RGS2(3xFLAG) was markedly impaired (Fig. 4, G and
H). However, the amphipathic -helical domain proved
insufficient to promote degradation because a GFP fusion
protein bearing residues 16–80 of RGS2, which removes
the N-terminal hydrophobic motif but preserves the am-
phipathic -helical motif (Fig. 4A), was as proteolytically
stable as GFP (Fig. 4, C and D). Thus, apart from the identity
of the amino acid residue at position 2, RGS2 degradation
requires a novel bipartite degradation motif consisting of a
hydrophobic region near the N terminus and an amphipathic
-helix located more distally.
The bipartite degradation signal of RGS2 is not essential for
interaction with CUL4B or ubiquitination
To determine how this bipartite motif promotes proteolytic
degradation of RGS2, we determined whether it is required for
interaction with ubiquitin E3 ligases implicated previously
in RGS2 degradation (36, 37). Interaction between Met-1–
RGS2(3xFLAG) and a His-Myc–tagged form of the E3 ligase
TEB4 was studied, but we were unable to detect interaction
using previously reported chemical cross-linking and co-im-
munoprecipitation methods (see “Discussion”).3 In contrast,
interaction between transiently expressed Met-1–RGS2
(3xFLAG) and E3 ubiquitin ligase complexes containing Myc-
tagged CUL4B was detected readily by co-immunoprecipita-
tion (Fig. 5A). However, this interaction was largely unaffected
by mutations that dramatically impair RGS2 degradation (Fig.
5A), suggesting that these mutations blunt RGS2 proteolysis by
events subsequent to E3 ligase interaction such as ubiquitin
attachment or proteasome recognition. We therefore deter-
mined whether mutations that strongly impair proteolysis of
RGS2 have concomitant effects on ubiquitination. Results
showed that mutations disrupting either half of the bipartite
degradation signal reduced but did not eliminate ubiquitina-
tion of transiently expressed Met-1–RGS2(3xFLAG) (Fig. 5, B
and C). The bipartite degradation motif of RGS2 therefore
affects ubiquitin conjugation.
RGS2 degradation determines agonist efficacy in
Gq/11-coupled receptor signaling
Using our collection of RGS2 variants that are proteolyzed at
different rates, we developed a system to determine how degra-
dation impacts the ability of RGS2 to regulate Gq/11-coupled
GPCR signaling. In contrast to assays used previously (ERK
activity (37); inositol phosphate accumulation (35)) providing
static measures of signaling end points, we used Ca2 signaling
to provide quantitative, kinetically resolved data to determine
how RGS2 degradation impacts the amplitude or dynamics of
agonist-evoked Gq signaling. For these purposes we used trans-
fected Twitch-2B (48), a FRET reporter of Ca2 signaling, to
monitor agonist (carbachol) stimulation of Gq/11-coupled
muscarinic receptors in HEK 293 cells transfected with wild-
type or mutant forms of RGS2 that are degraded at different
rates.We chose not to studymutants affecting the amphipathic
-helical region because they abrogate plasma membrane tar-
geting and function of RGS2 (49); instead we studiedmutations
affecting the hydrophobic motif near the N terminus.
First, we determined whether proteolysis sets the expres-
sion level of RGS2 and affects the ability of this protein
to regulate Gq/11-coupled GPCR-evoked Ca2 signaling.
Results showed that expression levels of the proteolytically
stable F6D derivative and the proteolytically unstable Q2L
derivative were, respectively, higher and lower than wild-
Figure5.Proteolysis-resistantRGS2mutants interactwithCUL4Bandreducebutdonoteliminateubiquitination.A,wild-typeandproteolysis-resistant
mutant forms of Met-1–RGS2(3xFLAG) interact with CUL4B. HEK 293 cells co-transfected with Myc-CUL4B and the indicated forms of RGS2(3xFLAG) were
incubatedwithMG-132 for 4 h, lysed, immunoprecipitatedwith anti-FLAG (M2) affinity beads and analyzed by immunoblotting. B, ubiquitination of wild-type
and proteolytically stable variants of Met-1–RGS2(3xFLAG). HEK 293 cells were co-transfected with HA-ubiquitin and the indicated variants of RGS2(3xFLAG),
incubatedwithMG-132 for 8 h and immunoprecipitatedwith anti-HA agarose beads. Cell lysates and immunoprecipitates were analyzed by immunoblotting
with anti-FLAGantibody todetect unmodified andubiquitinatedRGS2(3xFLAG) (designatedUbn-RGS2).C, quantificationof ubiquitinationefficiency. The ratio
of ubiquitinated RGS2 (IP:HA, IB:FLAG) to unubiquitinated RGS2 (input) (Ubn-RGS2/RGS2) was quantified for the indicated forms of RGS2(3xFLAG) and normal-
ized relative to the ubiquitination efficiency of Met-1–RGS2(3xFLAG). Statistical significance was determined by one way analysis of variance followed by
Bonferroni post hoc test. Error bars denote S.E. *, p 0.001 versusMet-1–RGS2(3xFLAG).
RGS2 proteolysis dynamically regulates Gq/11 signaling
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type Met-1–RGS2(3xFLAG) (Fig. 6A). Furthermore, expres-
sion of Met-1–RGS2(3xFLAG) and its F6D derivative were lin-
early proportional to the amount of transfected plasmid (Fig. 6,
A and B). Expression of the Q2L derivative also increased with
the amount of transfected plasmid (Fig. 6A), but below the lin-
ear range of detection. We then compared carbachol-evoked
Ca2 responses in HEK 293 cells lacking or expressing increas-
ing levels of transfected wild-type or mutant forms of Met-1–
RGS2(3xFLAG). In these cells, Gq/11 rather than Gi/o mediates
carbachol-evoked Ca2 fluxes, as indicated by insensitivity to
pertussis toxin.3 A maximally effective concentration of carba-
chol evoked a rapid and robust Ca2 response in control cells
not transfected with RGS2 (Fig. 6C). In response to increasing
levels of transfected wild-type MET-1–RGS2(3xFLAG), ago-
nist efficacy (maximal Ca2 response) diminished (Fig. 6,C and
D). Expression of the proteolytically unstable Q2L mutant also
reduced agonist efficacy, but required 2-fold more trans-
fected plasmid to produce an inhibitory effect equivalent to
Met-1–RGS2(3xFLAG) (Fig. 6,C andD). Conversely, the slowly
degraded F6Dderivative required3-fold less transfected plas-
mid to elicit an effect equivalent to Met-1–RGS2(3xFLAG)
(Fig. 6, C and D). These results were not because of differences
in plasma membrane localization of Met-1–RGS2(3xFLAG)
and its Q2L and F6D variants as indicated by fluorescence
confocal microscopy (Fig. 6E), in contrast to the cytoplasmic
mislocalization of RGS2 mutants bearing a disrupted
amphipathic -helix (49). Taken together these results indi-
cated that proteolytic degradation regulates agonist efficacy
in Gq/11-coupled GPCR signaling by determining expression
levels of RGS2.
RGS2 degradation facilitates recovery of Gq/11-coupled GPCR
signaling
RGS2 mRNA expression in many cell types is up-regulated
strikingly and transiently in response to various GPCR agonists
or other extracellular signals or second messengers, and then
declines to baseline within1–2 h (29–31, 33), suggesting that
this process potentially functions as a transiently acting feed-
back loop that blunts, or desensitizes, GPCR signaling. If so,
proteolytic degradation could be important for determining
not only peak RGS2 protein expression levels and the conse-
quent magnitude of signal attenuation, as indicated above, but
also the kinetics with which cells regain agonist responsiveness
or resensitize as RGS2 mRNA expression declines, thereby ter-
minating the inhibitory feedback loop.
We tested this hypothesis by adapting the Ca2 signaling
system described above to study how cells regain agonist
responsiveness over time after synthesis of Met-1–RGS2
(3xFLAG) is stopped by blocking new protein synthesis with
CHX. The proteasome dependence of the resensitization pro-
cess was studied by performing experiments with or without
the proteasome inhibitor MG-132, and by comparing cells
transfected with wild-type, fast (Q2L), or slowly degrading
(F6D) forms of Met-1–RGS2(3xFLAG). In each experiment
transfected HEK 293 cells were treated with CHXwith or with-
out MG-132. At various times thereafter, cells were stimulated
with a maximally effective concentration of carbachol. The
recovery of agonist efficacy over time after RGS2 synthesis
stops and proteolysis proceeds was determined by measuring
peak agonist-evoked Ca2 response following addition of CHX
without or with MG-132. Control experiments using cells
Figure 6. RGS2 degradation determines expression levels and agonist efficacy. A, proteolytic degradation sets protein expression levels of Met-1–
RGS2(3xFLAG) and its variants. HEK 293 cellswere co-transfectedwith a fixed amount of a plasmid expressing theCa2 FRET reporter Twitch-2B and increasing
amounts of plasmid (13, 25, 50, 75, or 100 ng/well) expressingMet-1–RGS2(3xFLAG) or its Q2L and F6D variants. A single representative immunoblot is shown
to indicate the relative expression of Met-1–RGS2(3xFLAG) and its variants with increasing amount of transfected plasmid DNA. Equal transfection efficiency
was indicatedby expressionof Twitch-2Bdetectedwith aGFP antibody.B, expressionofMet-1–RGS2(3xFLAG) and its F6Dvariant is linearly proportional to the
amountofplasmid transfected; expressionof theQ2Lderivativewasbelow the linear range,whichprecludedquantification.QuantifiedMet-1–RGS2(3xFLAG)/
Twitch-2B ratios were plotted relative to the highest value observed. Correlation coefficients (R2) of data fitted to a simple linear regression are indicated. Error
bars indicate S.E. C, effect of increasing expression of Met-1–RGS2(3xFLAG) or its variants on Gq/11-coupled muscarinic receptor signaling. HEK 293 cells
transfected as in (A) were treated at the indicated time (arrow) with carbachol (100M). Changes in [Ca2]i detected over time by the FRET reporter Twitch-2B
are reported as R/Ro. Experimental traces from cells transfected with various amounts of plasmid expressing Met-1–RGS2(3xFLAG) or its variants are color
coded as indicated. Traces shown are averages of three independent experiments performed in triplicate. D, agonist efficacy as a function of Met-1–
RGS2(3xFLAG) expression level. Agonist efficacywasquantifiedbynormalizingpeakCa2 response ((maxR/RowithRGS2)/(maxR/RonoRGS2)100). Error
barsdenote S.E. *,p0.05, **,p0.001 versusMet-1–RGS2(3xFLAG). E, subcellular localizationofMet-1–RGS2(3xFLAG) and its variants inHEK293 cells treated
with vehicle or MG-132 as detected by fluorescence confocal microscopy. Scale bar is 10 m. Data shown are representative of three or more independent
experiments.
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untransfected with RGS2 indicated that agonist efficacy
changed insignificantly over 40min after CHX treatment either
without or with MG-132 (Fig. 7A), showing that during this
time course the functions of endogenously expressed signaling
or regulatory proteins are independent of proteasome-medi-
ated degradation.
In contrast, clear evidence of proteasome-dependent resen-
sitization was obtained with cells expressing wild-type Met-1–
RGS2(3xFLAG). These cells initially exhibited blunted agonist
response, which recovered significantly within 40 min after
new protein synthesis was inhibited with CHX (Fig. 7, A
and B). This recovery process was proteasome-dependent
because it was blunted when cells were treated with CHX
and MG-132 (Fig. 7, A and B). Similarly, cells expressing the
unstable RGS2-Q2L(3xFLAG) mutant recovered agonist
responsiveness in a proteasome-dependentmanner (Fig. 7,A
and B). However, in this case, recovery occurred more
quickly, as expected if RGS2-Q2L(3xFLAG) is proteolyzed
faster than Met-1–RGS2(3xFLAG). Conversely, cells express-
ing the slowly degrading RGS2-F6D(3xFLAG) mutant resensi-
tized little within 40min after CHX treatment either without or
with MG-132 (Fig. 7, A and B). These results provided the first
direct evidence indicating that proteasome-mediated degrada-
tion of RGS2 determines the rate and extent that cells recover
agonist responsiveness once RGS2 expression ceases. Taken
together, our findings indicate that proteolytic degradation of
RGS2 can serve at least two functions: 1) determine agonist
efficacy by setting expression levels of RGS2 protein and 2)
determine the rate that cells recover agonist responsiveness as
RGS2 expression declines.
RGS2 proteolysis regulates agonist-evoked contraction
of resistance arteries
To explore the physiological significance of RGS2 proteoly-
sis, we studied contraction of resistance arteries, which is reg-
ulated by RGS2 and critical for blood pressure control. Indeed,
the absence of RGS2 augments vascular contraction evoked by
Gq/11-coupled GPCR agonists (16, 47), and RGS2 mRNA
expression in vascular smooth muscle cells is up- and then
down-regulated following stimulation by angiotensin II (29).
Accordingly, proteolytic degradation of RGS2 might facilitate
recovery of vascular contractility as RGS2 mRNA expression
declines.
To probe such regulatory processes in isolated resistance
arteries, we explored whether vascular contractility is affected
by proteolytic degradation of RGS2. Because the proteasome
inhibitor MG-132 had complex effects on contraction of iso-
lated mesenteric resistance arteries (MAs), we instead deter-
mined whether blocking protein synthesis with CHX affects
vascular contraction. We reasoned that if endogenous RGS2 is
Figure 7. Proteasome-mediateddegradationof RGS2 controls recovery of agonist responsiveness.A, recovery of agonist-evokedCa2 response (resen-
sitization) depends on proteasome-mediated degradation of RGS2. HEK 293 cells co-transfected with Twitch-2B and pcDNA3.1 (no RGS2), Met-1–
RGS2(3xFLAG) or its indicated variants were incubated with CHX without or with MG-132 for the indicated times (color coded) prior to stimulation with a
maximally effective concentration of carbachol (arrows). Traces shown are averages of three independent experiments performed in triplicate. B, quantifica-
tionof recovery of agonist responsiveness. Recoverywas calculated as the -fold-increase inpeak calcium responseover time followingadditionof CHXwithout
or with MG-132. Error bars indicate S.E. *, p 0.05; **, p 0.01 versus treatment with CHXMG-132.
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proteolytically unstable in wild-type MAs, CHX treatment
should phenocopy genetic deletion of RGS2.
We tested this prediction by using submaximal electrical
field stimulation (EFS) (40 V at 15Hz) ofMAs to release endog-
enous norepinephrine and ATP from sympathetic nerve termi-
nals embedded in the vessel wall, thereby activating Gq/11-cou-
pled 1-adrenergic and P2Y2 purinergic GPCRs in vascular
smoothmuscle cells and triggering vasoconstriction (51–53). If
the proteolytic half-life of RGS2 in MAs is similar to that of
transfected RGS2 (30 min), then treating wild-type MAs 1 h
with CHX would be sufficient for most of the preexisting pool
of RGS2 to be degraded. Indeed, we found that treating wild-
type MAs 1 h with CHX augmented EFS-evoked contraction
2.5-fold relative to vehicle controls (Fig. 8, A and B). As
expected if this effect was caused by degradation of RGS2, it
phenocopied themagnitude of EFS-evoked contraction in vehi-
cle-treated Rgs2/ MAs (Fig. 8, C and D). Moreover, CHX
failed to augment contraction ofRgs2/MAs (Fig. 8,C andD),
indicating that other signaling or contractile proteins were
affected insignificantly by CHX treatment. Accordingly, these
results support the hypothesis that proteolytic degradation of
RGS2 in resistance arteries occurs at rates competent to control
agonist responsiveness on physiologically relevant time scales.
Discussion
Here we have shown that proteolytic degradation of RGS2
facilitates temporal regulation of Gq/11-mediated signaling and
vascular contraction. We also have shown that mechanisms
mediating proteolytic degradation of RGS2 are considerably
more complex than appreciated previously.
In several cell types and organs, RGS2 mRNA expression is
strikingly and transiently up- and then down-regulated in
response to various extracellular stimuli, GPCR agonists, or
second messengers, potentially providing negative feedback of
signaling pathways controlled by RGS2 (34). By affecting the
level of RGS2 protein expressed, proteolytic degradation is
capable of determining the magnitude of the inhibitory effect
achieved by up-regulating RGS2mRNA expression. Moreover,
because our results show that proteolysis of RGS2 is kinetically
competent to determine how quickly agonist responsiveness
recovers after RGS2 expression ceases, this process also is capa-
ble of determining the rate that feedback regulation of cell sig-
naling is relieved as RGS2 mRNA expression declines. Addi-
tional mechanisms are likely to influence such outcomes
because cardiotonic steroids, PKC, and cGK can regulate RGS2
proteolysis (38–41), providing further control of feedback reg-
ulation of GPCR signaling by RGS2.
Our findings indicate that RGS2 proteolysis is more complex
mechanistically than appreciated previously. Beyond prior
understanding that RGS2 proteolysis via the Ac/N-end rule
pathway depends on N-terminal acetylation and the identity of
the amino acid at position 2 of the longest alternative transla-
tion product (37), we have found that RGS2 degradation
requires a novel bipartite signal consisting of a hydrophobic
region proximal to the N terminus and an amphipathic -heli-
cal region located more distally.
This novel bipartite degradation signal of RGS2 may facili-
tate proteolysis by several mechanisms. First, this signal may be
recognized directly by TEB4 (MARCH6) in the Ac/N-end rule
pathway. Indeed, TEB4 can bind in vitro to the first 10 residues
of RGS2 (37), which includes the N-terminal hydrophobic
region of the bipartite degradation motif but excludes the
amphipathic -helix. However, determining whether TEB4-
Figure8. Proteolytic degradationofRGS2 regulatesGq/11-evokedconstrictionof resistancearteries.A andB, representative traces showing constriction
of vehicle control (blue) or CHX-treated (1 h) (orange) wild-type (A) or RGS2-deficient (B) mesenteric arteries in response to 30 s electrical field stimulation
(bidirectional arrows). Traces representative of six independent experiments performedwith one vessel per animal for each genotype indicate the percentage
change in lumen diameter (% constriction) relative to baseline. C and D, quantitation of EFS-induced vasoconstriction. The magnitude of EFS-induced
constriction was calculated as the area under the curve (AUC). Mean AUC values	 S.E. are shown. **, p 0.01 versus control.
RGS2 proteolysis dynamically regulates Gq/11 signaling
J. Biol. Chem. (2017) 292(47) 19266–19278 19273
 at W
ashington U
niversity on D
ecem
ber 9, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
RGS2 binding mediates RGS2 degradation was precluded by
our failure to detect this interaction in cells despite using pre-
viously reported chemical cross-linking methods (37). Second,
TEB4 might recognize the amphipathic -helix of RGS2
because degradation signals in substrates targeted by the yeast
TEB4 homolog Doa10 include exposed hydrophobic faces of
amphipathic -helices (54). Third, the bipartite degradation
motif of RGS2 might be recognized indirectly by TEB4, as sug-
gested by studies of Doa10 showing that some substrates are
presented indirectly by Hsp70 and Hsp40 chaperones and co-
chaperones (55). Fourth, the bipartite degradation signal of
RGS2 may be recognized indirectly by the CUL4B/DDB1/
FBXO44 E3 ligase complex that target RGS2 for degradation,
because neither half of this signal is required for physical inter-
action between RGS2 and CUL4-containing complexes.
The bipartite degradation signal of RGS2 may function in
other steps of the proteolysis process. Indeed, our finding that
mutations disrupting these signals reduce but do not eliminate
ubiquitination of RGS2 is consistent with evidence in other
systems that degradation signals can affect selection of lysine
acceptor sites for ubiquitination, the efficiency of ubiquitin
transfer to substrates, or recognition or unfolding of ubiquiti-
nated substrates by the proteasome (56–59).
Mechanisms regulating the proteolysis of RGS2 also remain
to be elucidated in detail. Cardiotonic steroids, PKC, or cGK all
regulate RGS2 degradation (38–41), although whether these
mechanisms directly target RGS2 or the machinery that medi-
ates RGS2 degradation is unclear. PKC can directly phosphor-
ylate RGS2, but whether this is sufficient to inhibit RGS2
degradation has not been determined. Regulation of RGS2 deg-
radation by cGK activity apparently occurs by more than one
mechanism because inhibition of this protein kinase blunts
RGS2 degradation whereas inactivation of the cGK phosphor-
ylation sites in RGS2 promotes proteolysis.
In conclusion, by showing that proteolytic degradation of
RGS2 can facilitate temporal regulation of agonist responsive-
ness on physiologically relevant time scales, our findings sug-
gest that targeting proteolytic mechanisms might provide ave-
nues for treating diseases such as hypertension and anxiety that
have been linked to decreased RGS2 expression or function.
Various steps in processes that control proteolytic degradation
of RGS2 therefore may provide a multiplicity of targets to pur-
sue for therapy.
Experimental procedures
cDNAs
The plasmid pcDNA3.1 (Thermo Fisher Scientific) was used
to drive expression of all RGS2 constructs used in this study. All
constructs were prepared by PCR cloning using KAPA Taq po-
lymerase (Kapa Biosystems, catalog no. KK1006). All point
mutations were generated by site-directedmutagenesis, and all
deletion mutants were made by PCR-mediated ligation. Met-
1–RGS2(3xFLAG) used as a template for all RGS2 expression
constructs was generated by mutating all internal translation
start sites (ATG) to leucine (CTG). GFP fusion proteins were
generated by cloning PCR amplified fragments of RGS2 into
plasmid pcDNA3.1-N-MCS-GFP, which was generated by
cloning GFP from eGFP-N (Clontech) into pcDNA3.1.
Twitch-2B pcDNA3, which expresses a FRET-based Ca2
reporter, was a gift of Oliver Griesbeck (Addgene plasmid, cat-
alog no. 49531) (48). Expression plasmids for Myc-CUL4B and
HA-ubiquitin were gifts from Helen Piwnica-Worms (Univer-
sity of TexasMDAndersonCancerCenter). A plasmid express-
ing TEB4-His-Myc was a gift of Mark Hochstrasser (Yale Uni-
versity School of Medicine).
Antibodies and reagents
Mouse anti-FLAG (M2) (Sigma, catalog no. F1804); mouse
anti-actin (C4) (Millipore, catalog no. MAB1501); rabbit anti-
GFP (Abcam, catalog no. ab290, various lots); Odyssey infrared
secondary antibodies: goat anti-mouse IRDye 800CW (LI-
COR, catalog no. 926–32210, lot C30702–01), goat anti-rabbit
IRDye 680RD (LI-COR, catalog no. 926–68071, lot C3081502),
HRP conjugated mouse anti-FLAG (M2) (Sigma, catalog no.
A8592), HRP conjugated mouse anti-MYC (9e10) (Thermo
Fisher Scientific, catalog no. MA1–980-HRP, lot RD232005),
mouse anti-FLAG (M2) affinity gel (Sigma, catalog no. A2220,
various lots), mouse anti-HA agarose (Sigma, catalog no.
A2095, lot 026M4810V), cycloheximide (Sigma, catalog no.
C7698), MG-132 (Calbiochem, catalog no. 47479D), carbam-
oylcholine chloride/carbachol (Sigma, catalog no. C4382).
Cell culture and transfection
HEK 293 and A7r5 cells (ATCC, CRL-1444) were grown in
DMEM/F-12 (Thermo Fisher Scientific, catalog no. 11330–
032)with 10%FBS (Atlanta Biologicals, catalog no. S11150) and
penicillin/streptomycin (Thermo Fisher Scientific, catalog
no. 15140122) at 37 °C and 5% CO2 in a humidified incuba-
tor. Most transfections were performed with TransIT-LT1
(Mirus Bio, catalog no. MIR2305) according to the manufa-
cturer’s protocol.
Protein degradation assay
HEK 293 cells were co-transfected with the indicated
RGS2(3xFLAG) variants and GFP or transfected with the indi-
cated RGS2-GFP fusion variant for 20–24 h. Transfected cells
were treated with cycloheximide (30 g/ml) for the indicated
times, lysed, and harvested in radioimmunoprecipitation assay
(RIPA) buffer (150mM sodium chloride, 1% Triton X-100, 0.5%
sodiumdeoxycholate, 0.1% sodiumdodecyl sulfate, 50mMTris,
pH 8.0) with 1 cOmplete Protease Inhibitor (Roche, catalog
no. 11697498001). Cleared lysates were mixed with Laemmli
buffer (25% v/v glycerol, 2% w/v sodium dodecyl sulfate, 0.01%
w/v bromophenol blue, 62.5 mMTris pH 6.8) and processed for
Western blot analysis with the Odyssey Infrared Imaging Sys-
tem (LI-COR).
Western blot detection with the Odyssey Infrared Imaging
System
Lysates were resolved with 15% SDS-PAGE and transferred
to Immobilon(P)-FL fluorescence optimized PVDF membrane
(Millipore, catalog no. IPFL00010).Membraneswere incubated
in blocking buffer (5% w/v milk in TBST (25 mM Tris pH 7.2,
NaCl 150 mM, 2.7 mM KCl, 0.1% v/v Tween 20)) and then with
the appropriate primary antibody (mouse anti-FLAG (M2),
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rabbit anti-GFP (ab290), ormouse anti-actin (C4)).Membranes
were washedwith TBST at least three times, incubatedwith the
appropriate infrared dye-conjugated secondary antibody (anti-
mouse IR800 or anti-rabbit IR680), washed at least three times,
and imaged with Odyssey Infrared Scanner. Data were quanti-
fied with image analysis software Odyssey v2.1. For assays
involving RGS2(3xFLAG) variants, Western blot signals for
FLAGwere normalized toGFP. For assays involvingRGS2-GFP
fusion variants, Western blot signals for GFP were normalized
to actin. Relative protein levels are expressed as the percentage
ofRGS2(3xFLAG)/GFPorRGS2-GFP/actin at time
0.A stan-
dard curve relating protein expression to signal intensity was
generated to establish the linear range of detection.Only signals
within the linear range of detection were quantified and used
for analysis. At least three independent experiments were per-
formed for each analysis.
Western blotting procedure for detection by
chemiluminescence
Lysates were prepared and resolved with SDS-PAGE as
described above, and transferred to Immobilon-P PVDF mem-
brane (Millipore, catalog no. IPVH00010). Membranes were
processed as above and incubated with appropriate primary
and secondary antibodies. Membranes were incubated with
Clarity Western ECL Substrate (Bio-Rad Laboratories, catalog
no. 170–5060) and imaged with ChemiDoc Imaging System
(Bio-Rad Laboratories).
Co-immunoprecipitation of RGS2with CUL4
HEK 293 cells co-transfected with Myc-tagged CUL4B and
the indicated RGS2(3xFLAG) variants were incubated with
MG-132 (10M) for 4 h, lysed, and harvested in radioimmuno-
precipitation assay buffer. Cleared lysates were immunopre-
cipitated with anti-FLAG (M2) affinity gel and eluted by boiling
in Laemmli buffer. Lysates and eluates were resolved by 12%
SDS-PAGE, transferred to PVDF, and processed for Western
blotting. FLAG- and Myc-tagged proteins were detected with
HRP-conjugated anti-FLAG (M2) and HRP-conjugated anti-
Myc (9e10) primary antibodies, respectively.
Immunoprecipitation of proteins conjugated to HA-tagged
ubiquitin
HEK 293 cells co-transfected with HA-tagged ubiquitin and
the indicated RGS2(3xFLAG) variants were incubated with
vehicle (DMSO) or MG-132 (10 M) for 8 h and lysed in PBS/
Triton X-100 buffer (1 mM potassium phosphate, 155 mM
sodium chloride, 3 mM sodium phosphate, 1% v/v Triton
X-100, 10 mM N-ethylmaleimide (Pierce, catalog no. 23030),
1 cOmplete Protease Inhibitor). Cleared lysates were immu-
noprecipitated with anti-HA agarose and eluted by boiling in
Laemmli buffer. Lysates and eluates were resolved by 12% SDS-
PAGE, transferred to PVDF, and processed for Western blot-
ting as described above. FLAG-tagged RGS2 was detected with
HRP-conjugated anti-FLAG (M2) primary antibody. Western
blots were quantifiedwith Image Lab (Bio-Rad Laboratories). A
standard curve for protein amount to signal intensity was gen-
erated to establish the linear range of detection. Only signals
within the linear range of detection were used.
Agonist-evoked Ca2 flux assay
HEK 293 cells co-transfected with FRET-based Ca2 sensor
Twitch-2B (48) and the indicatedRGS2(3xFLAG) variantswere
plated on a 96-well clear bottom black wall plate (Costar, cata-
log no. 3603) coated with poly-D-lysine (Sigma, catalog no.
P0899). 20–24 h later, the culture medium was replaced with
imaging buffer (125 nMNaCl, 5mMKCl, 1.5mMMgCl2, 1.5mM
CaCl2, 10 mM D-glucose, 20 mM HEPES, pH 7.4) (60) and
assayed immediately at 37 °C with a Synergy H4 Hybrid Reader
(BioTek) equipped with an injection pump. For assays in Fig. 7,
cells were preincubated in CHX/MG-132 in imaging buffer for
the indicated time periods prior to agonist stimulation. For all
assays, baseline [Ca2]i was measured first, then cells were
stimulated by agonist injection and measurement of [Ca2]i
resumed until signals plateaued. FRET detected by Twitch-2B
was measured every 49 ms by exciting the FRET donor with
420/20 bandpass filter, and simultaneously detecting donor and
acceptor emissions with 480/20 and 540/20 bandpass filters,
respectively. A dichroic mirror with a 455-nm cutoff was used
to separate excitation and emission light paths. FRET, or
changes in [Ca2]i,, was expressed ratiometrically, as seen in
Equation 1:
R
Ro

FRET ratio baseline FRET ratio
baseline FRET ratio
(Eq. 1)
where FRET ratio
 (540 nmemission/480 nmemission) at any time
point, and the baseline FRET ratio
 average of (540 nmemission/
480 nmemission) prior to agonist stimulation.
Confocal microscopy
HEK 293 cells were transfected using Lipofectamine 2000
(Thermo Fisher Scientific, catalog no. 11668) according to the
manufacturer’s protocol. After 6 h, the cells were plated on
poly-D-lysine (1 g/ml) coated glass coverslips and incubated
for 24 h. Cells were treated 4 h withMG-132 (10M) or vehicle
(DMSO). Cells were fixedwith 4% paraformaldehyde in PBS for
15 min at room temperature and washed with PBS. Fixed cells
were permeabilized with 0.5% Triton X-100 in PBS for 10 min
at room temperature. Cells then were incubated for at least 30
min at room temperature in blocking buffer (1% BSA (Sigma
catalog no. A2153), 0.1% cold water fish skin gelatin (Sigma,
catalog no. G7765), 0.3%TritonX-100 in PBS). Cells were incu-
bated with mouse anti-FLAG (M2) primary antibody (Sigma,
catalog no. F1804, lot. SLBN5629V) in blocking buffer over-
night at 4 °C, followed by washes with PBS containing 0.3%
Triton X-100. Cells were incubated in anti-mouse Alexa Fluor
488 secondary antibody (Invitrogen, catalog no. A11001, lot
1696425) in blocking buffer containing 5% goat serum (Sigma,
catalog no. G9023) at room temperature for 1 h and then
washed with 0.3% Triton X-100 PBS. The coverslips were
mounted in VECTASHIELDAntifadeMountingMedium con-
taining DAPI (Vector Laboratories, catalog no. H-1200).
Animals
All animal experiments were conducted under protocols
approved by the Institutional Animal Care and Use Committee
of Drexel University, in accordance with the U.S. Animal Wel-
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fare Act. Experiments used congenic 2- to 3-month-old male
and female Rgs2/ and wild-type mice in the Charles River
C57BL/6 genetic background. The generation of Rgs2/mice
has been described previously (15). Mice were provided access
to food and water ad libitum in facilities maintained at 22 °C
with a 12-h light/dark cycle.
Mesenteric artery contraction studies
Mice were euthanized by deep anesthesia with ketamine/
xylazine (ketamine, 43 mg/kg, i.p., and xylazine, 6 mg/kg, i.p.)
followed by cervical dislocation. The gutwas excised andplaced
in chilled physiological saline solution buffer with the following
composition (mM): 140 NaCl, 5 KC1, 1.2MgSO4, 2.0 CaC12, 10
sodium acetate, 10 HEPES, 1.2 Na2H2PO4, 5 glucose, and pH
adjusted to 7.4 with NaOH. Second order mesenteric arteries
and their associated nerve terminals were isolated and trans-
ferred into a vessel chamber, cannulated at both ends with glass
pipettes, and secured with nylon ligature as described previ-
ously (50). Intraluminal pressure and vessel bath temperature
were maintained by servo-controlled pressure pump and tem-
perature control systems. The vessel lumen and chamber were
filledwith PSS buffer. After 30min equilibration at 37 °C and 60
mmHg, vessel viability was tested with increasing concentra-
tions (20, 40, 60, 80 mM) of high potassium-PSS solution to
assess maximal intrinsic contraction. After extensive washing
with PSS buffer, electrical field stimulation (40 V, at 15 Hz for
30 s) was used to release endogenous neurotransmitter (norepi-
nephrine) and elicit receptor-evoked contraction. Cannulated
vessels from wild-type and Rgs2/ mice were subjected once
to EFS-induced constriction, followed by 15 min washout with
PSS buffer. Arteries then were incubated with CHX (30 g/ml
for 1h) to block synthesis of RGS2, allowing proteolytic degra-
dation to occur before a second EFS stimulus was applied. EFS-
induced vasoconstriction was recorded as the percentage of
reduction from baseline of vessel lumen diameter, and quanti-
fied as the total area under the curve (AUC) during EFS (30 s).
AUC data were calculated as mean values	 S.E.
Statistical analysis
Unless stated otherwise, statistical significance was deter-
minedwith two-way analysis of variance (ANOVA) followed by
Bonferroni post hoc test. Paired Student’s t test was used for
statistical analysis of artery contraction data.
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